Basic HTML Version
74
VOLUME 9 NUMBER 2 • JUNE 2012
REPORT
SA JOURNAL OF DIABETES & VASCULAR DISEASE
Fig. 6.
Change in FPG (A) and post-breakfast PPG (B) levels after 24 weeks
of treatment with BIAsp 30 ± OGLDs in people previously receiving BHI 30
therapy.
Fig. 7.
Change in total, major, nocturnal and minor hypoglycaemia after 24
weeks of treatment with BIAsp 30 ± OGLDs.
A
B
months (Fig. 5), compared to their baseline treatment on premixed
human insulin. Mean FPG and PPG levels were also significantly
reduced (Fig. 6), and importantly, reported rates of hypoglycaemia
were significantly lower at six months, compared with baseline
(Fig. 7).
Improvement in quality of life
This extensive quality-of-life evaluation using the validated EQ-5D
questionnaire in the total cohort of 66 726 patients included
in the A
1
chieve study provides positive re-enforcement for both
clinicians and patients who have differing but important concerns
regarding insulin usage in type 2 diabetes patients. Overall,
the quality of life of patients starting insulin with, or switching
to insulin detemir, insulin aspart or biphasic insulin aspart 30
experienced significantly increased improvements across all five
component health dimensions.
References
Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C,
1.
et al
. An
observational non-interventional study of people with diabetes beginning or
changed to insulin analogue therapy in non-Western countries: the A
1
chieve
study.
Diabetes Res Clin Pract
2011;
94
(3): 352–363.
Hussein Z, Shah S, Gonzalez-Galvez G, Latif Z, Home P,
2.
et al
. Effect of adding
insulin aspart to basal insulin in clinical practice: results from the global A
1
chieve
observational study. Presentation from IDF 2011.
Litwak L, Haddad J, Su Yen G, Chakkarwar P, Baik SH. Improved glycaemic
3.
control after transferring basal insulin from glargine to detemir in type 2 diabetes:
subgroup analyses of A
1
chieve. Presentation from IDF 2011.
Hasan MI, Yuxiu L, Naggar NE, Khamseh ME,
4.
et al
. Safety and efficacy of biphasic
insulin aspart in people with type 2 diabetes switched from premixed human
insulin: results from A
1
chieve study. Presentation from IDF 2011.